Page last updated: 2024-10-27

flutamide and Metastase

flutamide has been researched along with Metastase in 48 studies

Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.

Research Excerpts

ExcerptRelevanceReference
"The National Cancer Institute of Canada (NCIC) Clinical Trials Group conducted a phase II study of the oral antiandrogen flutamide in 33 patients with metastatic breast cancer."7.67Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. ( Bramwell, VH; Eisenhauer, EA; Logan, DM; Paterson, AH; Perrault, DJ; Stewart, DJ, 1988)
"In a recent intergroup study under the auspices of the National Cancer Institute, 603 eligible patients with newly diagnosed disseminated adenocarcinoma of the prostate were prospectively randomized in a double-blinded clinical trial to receive either a gonadotropin-releasing hormone analogue (leuprolide) and a nonsteroidal antiandrogen (flutamide) or leuprolide and placebo."5.07The use of flutamide in hormone-refractory metastatic prostate cancer. ( Benson, RC; Blumenstein, BA; Crawford, ED; Eisenberger, MA; McLeod, DG; Spaulding, JT; Spicer, D, 1993)
"The National Cancer Institute of Canada (NCIC) Clinical Trials Group conducted a phase II study of the oral antiandrogen flutamide in 33 patients with metastatic breast cancer."3.67Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. ( Bramwell, VH; Eisenhauer, EA; Logan, DM; Paterson, AH; Perrault, DJ; Stewart, DJ, 1988)
"The number of patients who died of prostate cancer up to this time is insufficient for a definitive analysis of specific survival."2.71Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892. ( Collette, L; de Reijke, TM; Debois, M; Kurth, KH; Mattelaer, J; Pavone-Macaluso, M; Schröder, FH; van Velthoven, RF; Whelan, P, 2004)
"A total of 51 patients with metastatic prostate cancer underwent a 6-months period of continuous maximal androgen blockade (MAB) consisting of leuprorelin (3."2.71Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer? ( Avances, C; Lucas, C; Maubach, L; Mottet, N; Sene, E; Wolff, JM, 2005)
"Patients with localized prostate cancer receiving adjuvant chemotherapy had a higher initial objective response rate (95% vs 53%, P = 0."2.69Adjuvant mitozantrone chemotherapy in advanced prostate cancer. ( Halford, S; Lynch, M; Rigg, A; Roylance, R; Wang, J; Waxman, J, 2000)
"To review the outcome of therapy with maximal androgen blockade and compare the efficacy and safety of bicalutamide and flutamide, each used in combination with luteinizing hormone-releasing hormone analogue (LHRH-A) therapy, in patients with untreated metastatic (Stage D2) prostate cancer."2.68Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group. ( Block, N; Jones, J; Kolvenbag, G; Patterson, AL; Sarosdy, M; Schellhammer, P; Sharifi, R; Soloway, M; Venner, P; Vogelzang, N, 1996)
"Of 102 patients with metastatic prostate cancer, 52 were treated with orchidectomy and 50 with CHB; 22 of these received a LHRH analog + Flutamide and 28 orchidectomy + Flutamide."2.68[Final results of complete hormone blockade versus monotherapy in prostatic metastatic cancer. PSA implications]. ( de Torres, JA; Encabo, G; López Pacios, MA; Lorente, JA; Morote, J; Soler Roselló, A; Vallejo, C, 1995)
"Flutamide is a novel antiandrogen with fewer side effects."2.68Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. ( Blum, R; Chang, A; Davis, T; Fisher, H; Hahn, R; Khanna, O; Rosenthal, J; Schinella, R; Trump, D; Witte, R; Yeap, B, 1996)
"In patients with > 5 sites of bone metastasis (D2max), the corresponding periods were 9 and 14 months (p = 0."2.68Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. ( Hubmer, G; Lehnert, M; Pummer, K; Stettner, H, 1997)
"Prostate cancer is the most common cancer in American men today."2.67Controversies in the treatment of metastatic prostate cancer. ( Blumenstein, BA; Crawford, ED; Dorr, FA; Eisenberger, MA; McLeod, DG, 1992)
" In order to investigate the optimal way to eliminate tumor flare, we have treated patients with one of three different antiandrogen regimens used in combination with gonadotrophin-releasing hormone (GnRH) agonist."2.66The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue. ( Abel, P; Cox, J; Farah, N; Fleming, J; Hewitt, G; O'Donoghue, EP; Sandow, J; Sikora, K; Waxman, J; Williams, G, 1988)
"The hormonal treatment of the prostate cancer grew rich of new therapeutic classes which are going to change the medical care of the prostate cancer in the coming years and the urologist must play its full part."2.49[Hormonal treatment in prostate cancer]. ( Bastide, C; Bruyère, F; Guy, L; Karsenty, G; Rozet, F, 2013)
"For patients with nonmetastatic prostate cancer, castration alone might be adequately practical and efficient."1.36Efficacy of maximal androgen blockade versus castration alone in the treatment of advanced prostate cancer: a retrospective clinical experience from a Chinese medical centre. ( Chen, N; Chen, XQ; Huang, R; Huang, Y; Li, X; Wei, Q; Xia, J; Yang, YR; Zeng, H; Zhang, P; Zhu, YC, 2010)
"Treatment decisions for metastatic prostate cancer require the consideration of factors such as survival, quality of life, costs of care, and toxicities."1.30Treatment considerations for persons with metastatic prostate cancer: survival versus out-of-pocket costs. ( Bennett, CL; Matchar, DB; McCrory, DC, 1997)
"Patients with prostate cancer generally respond to androgen withdrawal therapy, but progression to androgen independence is frequently observed."1.30Response of prostate-specific antigen after androgen withdrawal and prognosis in men with metastatic prostate cancer. ( Akakura, K; Akimoto, S; Furuya, Y; Igarashi, T; Ito, H; Murakami, S; Shimazaki, J, 1998)
"Flutamide withdrawal, when combined with the simultaneous administration of aminoglutethimide, is a therapeutically active approach in patients with "hormone-refractory" prostate cancer."1.29Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. ( Cooper, M; Figg, WD; Headlee, D; Linehan, WM; Myers, CE; Sartor, O; Steinberg, S; Thibault, A; Tompkins, A; Weinberger, M, 1994)
"These data show that PSA synthesis by prostate cancer is reduced after androgen deprivation but that the PSA nadir and PSA doubling time following treatment provide important prognostic information."1.29Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer. ( Braswell, NT; Feliz, TP; Fowler, JE; Pandey, P; Seaver, LE, 1995)
"Flutamide has an incremental cost effectiveness more favorable than most accepted therapies."1.29Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer. ( Bennett, CL; Crawford, ED; Hillner, BE; McLeod, DG, 1995)
"In men with severely painful bony metastasis, an inexpensive drug used in Paget's disease, etidronate disodium, may be palliative."1.27Advances in the treatment of metastatic prostatic cancer. ( Elder, JS; Gibbons, RP, 1985)

Research

Studies (48)

TimeframeStudies, this research(%)All Research%
pre-199010 (20.83)18.7374
1990's25 (52.08)18.2507
2000's8 (16.67)29.6817
2010's5 (10.42)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bastide, C1
Bruyère, F1
Karsenty, G1
Guy, L1
Rozet, F1
Strum, SB1
Scholz, MC1
Robinson, D1
Sandblom, G1
Johansson, R2
Garmo, H1
Aus, G1
Hedlund, PO2
Varenhorst, E2
Yee, DS1
Lowrance, WT1
Eastham, JA1
Maschino, AC1
Cronin, AM1
Rabbani, F1
Chen, XQ1
Huang, Y1
Li, X1
Zhang, P1
Huang, R1
Xia, J1
Chen, N1
Wei, Q1
Zhu, YC1
Yang, YR1
Zeng, H1
Damber, JE1
Hagerman, I1
Henriksson, P1
Iversen, P1
Klarskov, P1
Mogensen, P1
Rasmussen, F1
Corrie, P1
Mayer, A1
Shaw, J1
D'Ath, S1
Blagden, S1
Blesing, C1
Price, P1
Warner, N1
Pollack, A1
Grignon, DJ1
Heydon, KH1
Hammond, EH1
Lawton, CA1
Mesic, JB1
Fu, KK1
Porter, AT1
Abrams, RA1
Shipley, WU1
Nabi, G1
Seth, A1
Dinda, AK1
Gupta, NP1
Schröder, FH1
Whelan, P1
de Reijke, TM1
Kurth, KH1
Pavone-Macaluso, M1
Mattelaer, J1
van Velthoven, RF1
Debois, M1
Collette, L1
Martín-Lázaro, J1
Buján, JG1
Arrondo, AP1
Lozano, JR1
Galindo, EC1
Capdevila, EF1
Mottet, N1
Lucas, C1
Sene, E1
Avances, C1
Maubach, L1
Wolff, JM1
Isaacs, JT1
Weissman, RM1
Coffey, DS1
Scott, WW1
Sartor, O1
Cooper, M1
Weinberger, M1
Headlee, D1
Thibault, A1
Tompkins, A1
Steinberg, S1
Figg, WD1
Linehan, WM1
Myers, CE1
Fowler, JE2
Pandey, P2
Seaver, LE2
Feliz, TP2
Braswell, NT1
Soloway, MS2
Sharifi, R2
Wajsman, Z1
McLeod, D1
Wood, DP1
Puras-Baez, A1
Scher, HI1
Kelly, WK1
Hillner, BE2
McLeod, DG3
Crawford, ED3
Bennett, CL2
Oosterlinck, W1
Mast, P1
Benson, RC1
Eisenberger, MA2
Blumenstein, BA2
Spicer, D1
Spaulding, JT1
Schellhammer, P1
Block, N1
Soloway, M1
Venner, P1
Patterson, AL1
Sarosdy, M1
Vogelzang, N1
Jones, J1
Kolvenbag, G1
Morote, J1
Vallejo, C1
Lorente, JA1
Encabo, G1
López Pacios, MA2
de Torres, JA1
Soler Roselló, A2
Zalcberg, JR1
Raghaven, D1
Marshall, V1
Thompson, PJ1
Chang, A1
Yeap, B1
Davis, T1
Blum, R1
Hahn, R1
Khanna, O1
Fisher, H1
Rosenthal, J1
Witte, R1
Schinella, R1
Trump, D1
Matchar, DB1
McCrory, DC1
Small, EJ1
Baron, AD1
Fippin, L1
Apodaca, D1
Datta, SN1
Thomas, K1
Matthews, PN1
Pummer, K1
Lehnert, M1
Stettner, H1
Hubmer, G1
Losa, M1
Grasso, M1
Giugni, E1
Mortini, P1
Acerno, S1
Giovanelli, M1
Boccon-Gibod, L1
Fournier, G1
Bottet, P1
Marechal, JM1
Guiter, J1
Rischman, P1
Hubert, J1
Soret, JY1
Mangin, P1
Mallo, C1
Fraysse, CE1
Furuya, Y1
Akimoto, S1
Akakura, K1
Igarashi, T1
Murakami, S1
Shimazaki, J1
Ito, H1
Rosendahl, I1
Kiebert, GM1
Curran, D1
Cole, BF1
Weeks, JC1
Denis, LJ1
Hall, RR1
Wang, J1
Halford, S1
Rigg, A1
Roylance, R1
Lynch, M1
Waxman, J2
Morote Robles, J1
Vila Barja, J1
de Torres Mateos, JA1
Dorr, FA1
Denis, L2
Smith, P1
Carneiro de Moura, JL1
Newling, D1
Bono, A1
Keuppens, F1
Mahler, C1
Robinson, M1
Sylvester, R2
De Pauw, M2
Robinson, MR1
Newling, DW1
Elder, JS1
Gibbons, RP1
Williams, G1
Sandow, J1
Hewitt, G1
Abel, P1
Farah, N1
Fleming, J1
Cox, J1
O'Donoghue, EP1
Sikora, K1
Senn, E1
Müller, J1
Alioth, H1
Flamm, J1
Fischer, M1
Perrault, DJ1
Logan, DM1
Stewart, DJ1
Bramwell, VH1
Paterson, AH1
Eisenhauer, EA1
Irwin, RJ1
Prout, GR1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
1911GCCC:Two Parallel, Single-arm, Open Label, Phase 2 Trials of Galeterone Alone or Galeterone Combined With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Standard Chemotherapy[NCT04098081]Phase 258 participants (Anticipated)Interventional2019-12-12Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

3 reviews available for flutamide and Metastase

ArticleYear
[Hormonal treatment in prostate cancer].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2013, Volume: 23, Issue:15

    Topics: Androgen Antagonists; Androgen Receptor Antagonists; Antineoplastic Agents, Hormonal; Benzamides; Co

2013
Total androgen blockade in the treatment of hormone-resistant metastasized prostate carcinoma. A literature review.
    Acta urologica Belgica, 1994, Volume: 62, Issue:1

    Topics: Androgen Antagonists; Cyproterone Acetate; Flutamide; Humans; Male; Neoplasm Metastasis; Prostatic N

1994
[LHRH agonists combined with antiandrogens in the treatment of metastasizing prostatic carcinoma].
    Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1985, Nov-26, Volume: 74, Issue:48

    Topics: Androgen Antagonists; Animals; Buserelin; Cyproterone; Cyproterone Acetate; Dogs; Drug Therapy, Comb

1985

Trials

25 trials available for flutamide and Metastase

ArticleYear
Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial.
    BJU international, 2010, Volume: 105, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Epidemiologic Methods; Flutamide; Goserelin; H

2010
Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial
    Scandinavian journal of urology and nephrology, 2011, Volume: 45, Issue:5

    Topics: Aged; Antineoplastic Agents, Hormonal; Cardiovascular Diseases; Combined Modality Therapy; Estradiol

2011
Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients.
    British journal of cancer, 2002, Sep-23, Volume: 87, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Flutamide; Gemci

2002
Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Apr-01, Volume: 21, Issue:7

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Diploidy; DNA, Neoplasm; F

2003
Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.
    European urology, 2004, Volume: 45, Issue:4

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Cyproterone Acetate; Disease Progression; Flutamide;

2004
Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer?
    Urologia internationalis, 2005, Volume: 75, Issue:3

    Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Drug Administration

2005
Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group.
    The Journal of urology, 1995, Volume: 154, Issue:2 Pt 1

    Topics: Aged; Combined Modality Therapy; Flutamide; Follow-Up Studies; Humans; Leuprolide; Male; Middle Aged

1995
Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment.
    The Journal of urology, 1995, Volume: 154, Issue:2 Pt 1

    Topics: Actuarial Analysis; Aged; Aged, 80 and over; Flutamide; Humans; Male; Middle Aged; Neoplasm Metastas

1995
The use of flutamide in hormone-refractory metastatic prostate cancer.
    Cancer, 1993, Dec-15, Volume: 72, Issue:12 Suppl

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Flutamide; Huma

1993
Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
    Urology, 1996, Volume: 47, Issue:1A Suppl

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Ant

1996
[Final results of complete hormone blockade versus monotherapy in prostatic metastatic cancer. PSA implications].
    Actas urologicas espanolas, 1995, Volume: 19, Issue:8

    Topics: Actuarial Analysis; Antineoplastic Agents, Hormonal; Flutamide; Gonadotropin-Releasing Hormone; Huma

1995
Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate--an Australian multicentre trial.
    British journal of urology, 1996, Volume: 77, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease Progres

1996
Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:8

    Topics: Administration, Oral; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal

1996
Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal.
    The Journal of urology, 1997, Volume: 157, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Humans; Hy

1997
Is prednisolone as good as flutamide in hormone refractory metastatic carcinoma of the prostate?
    The Journal of urology, 1997, Volume: 158, Issue:1

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; M

1997
Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    European urology, 1997, Volume: 32 Suppl 3

    Topics: Aged; Androgen Antagonists; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc

1997
Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
    European urology, 1997, Volume: 32, Issue:4

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Carcinoma; Flushing;

1997
Quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. European Organization for Research and Treatment of Cancer.
    The Prostate, 1999, Feb-01, Volume: 38, Issue:2

    Topics: Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Goserelin; Humans; Male; Neop

1999
Adjuvant mitozantrone chemotherapy in advanced prostate cancer.
    BJU international, 2000, Volume: 86, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chem

2000
[Complete hormonal blockade vs. monotherapy in the management of metastasizing prostatic cancer].
    Actas urologicas espanolas, 1992, Volume: 16, Issue:6

    Topics: Drug Evaluation; Flutamide; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms

1992
Controversies in the treatment of metastatic prostate cancer.
    Cancer, 1992, Jul-01, Volume: 70, Issue:1 Suppl

    Topics: Double-Blind Method; Drug Therapy, Combination; Flutamide; Humans; Leuprolide; Male; Neoplasm Metast

1992
Total androgen ablation: European experience. The EORTC GU Group.
    The Urologic clinics of North America, 1991, Volume: 18, Issue:1

    Topics: Aged; Buserelin; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy;

1991
Flutamide for prostate cancer.
    The Medical letter on drugs and therapeutics, 1989, Jul-28, Volume: 31, Issue:797

    Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Flutamide; Gonad

1989
The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue.
    American journal of clinical oncology, 1988, Volume: 11 Suppl 2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Cyproterone; Cyp

1988
[Complete androgen blockade (orchiectomy + flutamide) versus androgen blockade with cytostasis (orchiectomy + estramustine) in the treatment of virginal advanced prostate cancer].
    Wiener klinische Wochenschrift, 1988, Sep-09, Volume: 100, Issue:17

    Topics: Aged; Aged, 80 and over; Anilides; Clinical Trials as Topic; Combined Modality Therapy; Estramustine

1988

Other Studies

20 other studies available for flutamide and Metastase

ArticleYear
Adverse Health Effects of Intermittent vs Continuous Androgen Deprivation Therapy for Metastatic Prostate Cancer: Relating 33 Years of Patient Clinical Care.
    JAMA oncology, 2016, May-01, Volume: 2, Issue:5

    Topics: Androgen Antagonists; Androgens; Anilides; Drug-Related Side Effects and Adverse Reactions; Flutamid

2016
PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer.
    Urology, 2008, Volume: 72, Issue:4

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; K

2008
Efficacy of maximal androgen blockade versus castration alone in the treatment of advanced prostate cancer: a retrospective clinical experience from a Chinese medical centre.
    Asian journal of andrology, 2010, Volume: 12, Issue:5

    Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; China; Combined Modality Ther

2010
Computer based receptogram approach: an objective way of assessing immunohistochemistry of androgen receptor staining and its correlation with hormonal response in metastatic carcinoma of prostate.
    Journal of clinical pathology, 2004, Volume: 57, Issue:2

    Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Flutamide; Follow-Up

2004
Is photopatch testing useful in the investigation of photosensitivity due to flutamide?
    Contact dermatitis, 2004, Volume: 50, Issue:5

    Topics: Androgen Antagonists; Dermatitis, Photoallergic; Diagnosis, Differential; Drug Eruptions; Flutamide;

2004
Concepts in prostatic cancer biology: Dunning R-3327 H, HI, and AT tumors.
    Progress in clinical and biological research, 1980, Volume: 37

    Topics: Acid Phosphatase; Adenocarcinoma; Animals; Castration; Diethylstilbestrol; Disease Models, Animal; F

1980
Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer.
    Journal of the National Cancer Institute, 1994, Feb-02, Volume: 86, Issue:3

    Topics: Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Flutamid

1994
Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer.
    The Journal of urology, 1995, Volume: 153, Issue:6

    Topics: Actuarial Analysis; Aged; Aged, 80 and over; Flutamide; Humans; Male; Middle Aged; Neoplasm Metastas

1995
Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:8

    Topics: Aged; Combined Modality Therapy; Flutamide; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostate

1993
Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer.
    Urology, 1995, Volume: 45, Issue:4

    Topics: Aged; Cost-Benefit Analysis; Flutamide; Humans; Male; Models, Theoretical; Neoplasm Metastasis; Pros

1995
Estimating the cost-effectiveness of flutamide in metastatic cancer.
    Cancer treatment reviews, 1996, Volume: 22 Suppl A

    Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cost-Benefit Analysis; Flutamide; Human

1996
Treatment considerations for persons with metastatic prostate cancer: survival versus out-of-pocket costs.
    Urology, 1997, Volume: 49, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Costs and Cost Analysis; Flutamide; Humans; Male; Midd

1997
Metastatic prostatic adenocarcinoma presenting as a pituitary mass: shrinkage of the lesion and clinical improvement with medical treatment.
    The Prostate, 1997, Sep-01, Volume: 32, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Diagno

1997
Response of prostate-specific antigen after androgen withdrawal and prognosis in men with metastatic prostate cancer.
    Urologia internationalis, 1998, Volume: 60, Issue:1

    Topics: Aged; Aged, 80 and over; Analysis of Variance; Androgens; Blood Chemical Analysis; Bone Neoplasms; C

1998
EORTC protocol 30853: orchidectomy versus zoladex plus flutamide in the management of metastatic carcinoma of the prostate. Interim statistical analysis of the side effects of treatment.
    Cancer, 1990, Sep-01, Volume: 66, Issue:5 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Goserelin; Humans; Male; Neopl

1990
Advances in the treatment of metastatic prostatic cancer.
    The Western journal of medicine, 1985, Volume: 143, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Buserelin; Diethylstilbestrol; Flutamide; Gonadotrop

1985
Combined treatment with flutamide and surgical or medical (LHRH agonist) castration in metastatic prostatic cancer.
    Lancet (London, England), 1986, Jan-04, Volume: 1, Issue:8471

    Topics: Anilides; Combined Modality Therapy; Cyproterone; Flutamide; Gonadotropin-Releasing Hormone; Humans;

1986
Treatment of prostatic cancer. Newer forms of androgen deprivation.
    Postgraduate medicine, 1986, Volume: 80, Issue:1

    Topics: Androgen Antagonists; Cyproterone; Cyproterone Acetate; Flutamide; Humans; Male; Megestrol; Megestro

1986
Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study.
    Investigational new drugs, 1988, Volume: 6, Issue:3

    Topics: Anilides; Breast Neoplasms; Canada; Drug Evaluation; Flutamide; Follow-Up Studies; Humans; Neoplasm

1988
A new antiprostatic agent for treatment of prostatic carcinoma.
    Surgical forum, 1973, Volume: 24

    Topics: Adenocarcinoma; Anilides; Flutamide; Gynecomastia; Humans; Male; Neoplasm Metastasis; Prostatic Neop

1973